Skip to main content

Table 2 Baseline values for primary and secondary outcomes

From: Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients

 

Ezetimibe add- on group (n = 23)

Increased rosuvastatin (n = 20)

ApoB, g/L

1.06 ± 0.24

1.01 ± 0.38

ApoA1, g/L

1.54 ± 0.27

1.51 ± 0.32

ApoB:ApoA1

0.69 ± 0.21

0.72 ± 0.39

TC, mmol/L

5.23 ± 1.06

5.07 ± 0.50

LDL, mmol/L

2.80 ± 0.93

2.55 ± 0.58

HDL, mmol/L

1.21 ± 0.29

1.29 ± 0.40

TC:HDL

4.92 ± 2.25

4.25 ± 1.15

TG, mmol/L

2.55 ± 1.32

3.05 ± 1.52

AIP

0.29 ± 0.33

0.33 ± 0.33

Non-HDL-C, mmol/L

4.04 ± 1.05

3.78 ± 0.69

Glucose, mmol/L

6.54 ± 1.84

6.16 ± 2.22

hsCRP, mg/L

5.6 ± 10.20

2.8 ± 3.37

Creatinine, μmol/L

91 ± 22.50

98 ± 30.51

ALT, U/L

33 ± 13.80

34 ± 12.70

AST, U/L

29 ± 11.0

30 ± 11.40

CK, U/L

142 ± 100.0

177 ± 85.22

  1. Data are given as mean (±SD)
  2. apoB, apolipoprotein B; apoA1,apolipoprotein A1;TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; TG, triglycerides; AIP, atherogenic index of plasma; FBG, fasting blood glucose; hsCRP, high-sensitivity C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatine kinase